Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...

Dr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...

Dr Reddy's Laboratories has secured market authorization from Health Canada for its generic semaglutide injection. This marks a significant...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

India's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescriptio...

Fifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...

GLP-1 medications are prescription treatments used in the UK to manage type 2 diabetes and, in certain cases, medically supervised weight l...

Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...

The major pharmaceutical companies of the country reported a 10 per cent year-on-year (YoY) growth in the second quarter of FY25, largely d...

The new technique may enable researchers to quickly find drug candidates that activate cellular receptors in desired ways.

Arnab De, a PhD in Microbiology and Immunology from Columbia University, has developed the non-insulin drug candidate in collaboration with...